New Directors to the Board, page-16

Insulet objected to MannKind hiring and MannKind withdrew the offer

http://www.massdevice.com/ex-insulet-chief-desisto-out-before-hes-in-at-mannkind-personnel-moves/

Regardless of his faults he still possess insights into wearable drug delivery systems. He did a deal with Amgen for Nuelasta which nets Insulet (PODD) about $40MM in sales per year. They are also pursuing deals with other pharma's for drug delivery.

He also set the stage for sales growth with PODD revenue growing from $247MM in 2013 to $327MM in 2015. They also have a history of beating earnings expectations.

Additionally PODD had no problem raising funds this year. They just completed a $300MM convertible note offering with high enthusiasm from the purchasers.

The good comparison UNS has over PODD is the SG&A. PODD sells directly to the end user while UNS is a BtoB model hence our SG&A aka marketing and sales expenses are virtually none existent.

They also narrowed their loss to $1.2MM for the quarter ending June 2016.

An equivalent market cap to PODD would put UNS at $123.25USD.

Yup -- I'd take his advice.

He was a good get.